melody study

Melody study will investigate how well third doses of Covid-19 vaccines protect the immunocompromised

Hear the MELODY

The MELODY study will involve 36,000 immunocompromised people across the UK, starting with those with kidney and other organ transplants. The study will later include people with cancer and autoimmune diseases.

Immunocompromised people tend to be less likely to develop an antibody response after vaccination. Using an antibody test that participants can carry out at home, researchers will measure whether people have developed antibodies against the virus that causes Covid-19.

With news of the new Omicron variant and the speed at which it is spreading, this research is more vital than ever. Recognising who remains at high risk after vaccination will highlight the people who must remain cautious and will also identify those who may benefit from alternative protective treatments, such as monoclonal antibodies or the antiviral pill molnupiravir Click HERE.

Visit Kidney Research UK to find out more about MELODY

You can  find out more about MELODY at Kidney Research UK, Click HERE.

To register to take part in MELODY, go to

Transplant patients’ participation will be essential to ensure the study’s success – please share this with anyone you think will be interested.

MELODY is supported by the Medical Research Council in partnership with Kidney Research UK, the Cystic Fibrosis Trust, Blood Cancer UK and Vasculitis UK.

melody study

A reminder

The arrival of the Omicron variant is a reminder – if we needed it – that the pandemic has not gone away.

For reliable information on how kidney patients are affected, and new regulations about social distancing, working from home, face masks, etc, visit the dedicated page on the Kidney Care UK website, Click HERE.

The team have done a fantastic job in updating the page as new guidance is issued, and continue to cut through the confusion to provide credible information for kidney patients.